Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer: Application to doxorubicin and preliminary in Vitro and in Vivo studies

Cancer Research

Volumn 61, Issue 7, 2001, Pages 2843-2846

  Trouet, André ^a   Passioukov, Alexandre ^a   Van Derpoorten, Kim ^a   Fernandez, Anne Marie ^a   Abarca Quinones, Jorge ^a   Baurain, Roger ^a   Lobl, Thomas J ^b   Oliyai, Cecilia ^b   Shochat, Dan ^b   Dubois, Vincent ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b Corixa ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DOXORUBICIN; LEURUBICIN; N BETA ALANYLLEUCYLALANYLLEUCYLDOXORUBICIN; OLIGOPEPTIDE; PEPTIDASE; PRODRUG; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST TUMOR; CANCER CHEMOTHERAPY; CELL TYPE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVATION; DRUG EXPOSURE; DRUG METABOLISM; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG UPTAKE; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BIOTRANSFORMATION; BREAST NEOPLASMS; DOXORUBICIN; DRUG STABILITY; FEMALE; HUMANS; LETHAL DOSE 50; MALE; MICE; MICE, INBRED BALB C; OLIGOPEPTIDES; PRODRUGS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035300427     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Clinical strategies for cancer treatment: The role of drugs
2. Prodrugs of anticancer agents
3. Cancer invasion and tissue remodeling-cooperation of protease systems and cell types
4. Plasmin-activated prodrugs for cancer chemotherapy. 2. Synthesis and biological activity of peptidyl derivatives of doxorubicin
5. An approach towards more selective anticancer agents
6. Synthesis and biological evaluation of novel prodrugs of anthracyclines for selective activation by the tumor-associated protease plasmin
7. Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen
8. In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts
9. A peptide-doxorubicin "prodrug" activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo
10. Amino acid and dipeptide derivatives of daunorubicin. I. Synthesis, physicochemical properties, and lysosomal digestion
11. Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit
12. The anti-tumour effects of the prodrugs N-L-leucyl-doxorubicin and vinblastine-isoleucinate in human ovarian cancer xenografts
13. The antitumour activity of the prodrug N-L-leucyl-doxorubicin and its parent compound doxorubicin in human tumour xenografts
14. Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial
15. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent
16. Superior therapeutic efficacy of N-L-leucyl-doxorubicin versus doxorubicin in human melanoma xenografts correlates with higher tumour concentrations of free drug